

# BEST AVAILABLE COPY



(19) Europäisches Patentamt

European Patent Office

Office européen des brevets



(11) EP 1 174 136 A2

(12)

## EUROPEAN PATENT APPLICATION

(43) Date of publication:  
23.01.2002 Bulletin 2002/04

(51) Int Cl.7: A61K 31/44, A61K 9/36,  
A61K 9/52

(21) Application number: 01125523.9

(22) Date of filing: 09.02.1996

(84) Designated Contracting States:  
AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL  
PT SE

Designated Extension States:  
LT LV SI

(30) Priority: 09.02.1995 SE 9500478

(62) Document number(s) of the earlier application(s) in  
accordance with Art. 76 EPC:  
96902579.0 / 0 752 851

(71) Applicant: AstraZeneca AB  
151 85 Södertälje (SE)

(72) Inventors:  
• Lundberg, Per Johan  
431 83 Mölndal (SE)  
• Lövgren, Kurt  
431 83 Mölndal (SE)

### Remarks:


This application was filed on 25 - 10 - 2001 as a  
divisional application to the application mentioned  
under INID code 62.

### (54) Oral pharmaceutical dosage form containing a proton pump inhibitor

(57) A new oral pharmaceutical dosage form comprising a core material that contains a proton pump inhibitor, one or more alkaline reacting compounds and optionally pharmaceutical excipients having a water soluble separating layer and an enteric coating layer. The core material as such is alkaline reacting and the separating layer between the alkaline reacting core material

and the enteric coating layer is formed in situ as a water soluble salt between the alkaline reacting compound(s) and the enteric coating polymer. The invention also describes a new efficient process for the manufacture of such a dosage form comprising two functionally different layers in one manufacturing step, and its use in medicine.

Fig. 1




**Description****Field of the invention**

5 [0001] The present invention refers to new pharmaceutical formulations comprising acid labile heterocyclic compounds with gastric inhibitory effect, in the following referred to as proton pump inhibitors. The new formulations are intended for oral use. Furthermore, the present invention refers to a new method for the manufacture of such a formulation and, the use of the new formulations in medicine.



**Background of the invention**

10 [0002] The proton pump inhibitors are for example compounds of the general formula I




20 wherein


Het<sub>1</sub> is




Het<sub>2</sub> is



or




or




45

X =



or



55

wherein

N in the benzimidazole moiety means that one of the carbon atoms substituted by R<sub>6</sub>-R<sub>9</sub> optionally may be ex-

EP 1 174 136 A2

changed for a nitrogen atom without any substituents;

R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub> are the same or different and selected from hydrogen, alkyl, alkoxy optionally substituted by fluorine, alkylthio, alkoxyalkoxy, dialkylamino, piperidino, morpholino, halogen, phenyl and phenylalkoxy;

R<sub>4</sub> and R<sub>5</sub> are the same or different and selected from hydrogen, alkyl and aralkyl;

R'<sub>6</sub> is hydrogen, halogen, trifluoromethyl, alkyl and alkoxy;



R<sub>6</sub>-R<sub>9</sub> are the same or different and selected from hydrogen, alkyl, alkoxy, halogen, halo-alkoxy, alkylcarbonyl, alkoxy carbonyl, oxazolyl, trifluoroalkyl, or adjacent groups R<sub>6</sub>-R<sub>9</sub> form ring structures which may be further substituted;

R<sub>10</sub> is hydrogen or forms an alkylene chain together with R<sub>3</sub> and

R<sub>11</sub> and R<sub>12</sub> are the same or different and selected from hydrogen, halogen or alkyl; and alkyl groups. alkoxy groups and moieties thereof may be branched and straight C<sub>1</sub>-C<sub>9</sub>-chains or comprise cyclic alkyl groups, for example cycloalkylalkyl.

Examples of proton pump inhibitors according to formula I are





[0003]







50

55

EP 1 174 136 A2





EP 1 174 136 A2



50

55



- 25 [0004] The proton pump inhibitors used in the dosage forms of the invention may be used in neutral form or in the form of an alkaline salt, such as for instance the  $Mg^{2+}$ ,  $Ca^{2+}$ ,  $Na^+$ ,  $K^+$  or  $Li^+$  salts, preferably the  $Mg^{2+}$  salts. Further where applicable, the compounds listed above may be used in racemic form or in the form of a substantially pure enantiomer thereof, or alkaline salts of the racemates or the single enantiomers.
- 30 [0005] Suitable proton pump inhibitors are for example disclosed in EP-A1-0005129, EP-A1-174 726, EP-A1-166 287, GB 2 163 747 and WO90/06925, WO91/19711, WO91/19712, and further especially suitable compounds are described in WO94/27988 and WO95/01977.
- 35 [0006] These proton pump inhibitors are, as already mentioned, useful for inhibiting gastric acid secretion in mammals and man. In a more general sense, they may be used for prevention and treatment of gastric-acid related diseases in mammals and man, including e.g. reflux esophagitis, gastritis, duodenitis, gastric ulcer and duodenal ulcer. Furthermore, they may be used for treatment of other gastrointestinal disorders where gastric acid inhibitory effect is desirable e.g. in patients on NSAID therapy, in patients with Non Ulcer Dyspepsia, in patients with symptomatic gastro-esophageal reflux disease, and in patients with gastrinomas. They may also be used in patients in intensive care situations, in patients with acute upper gastrointestinal bleeding, pre- and postoperatively to prevent aspiration of gastric acid and to prevent and treat stress ulceration. Further, they may be useful in the treatment of Helicobacter infections and diseases related to these.
- 40 [0007] These proton pump inhibitors are, however, susceptible to degradation/transformation in acidic reacting and neutral media. The degradation is catalyzed by acidic reacting compounds and the proton pump inhibitors are usually stabilized in mixtures with alkaline reacting compounds.
- 45 [0008] In respect to the stability properties of the proton pump inhibitors mentioned above, it is obvious that a proton pump inhibitor in an oral solid dosage form must be protected from contact with the acidic reacting gastric juice and the active substance must be transferred in intact form to that part of the gastrointestinal tract where pH is less acidic, neutral or alkaline and where rapid absorption of the pharmaceutically active substance, i.e. the proton pump inhibitor, can occur.
- 50 [0009] A pharmaceutical dosage form of these proton pump inhibitors is best protected from contact with acidic gastric juice by an enteric coating layer. In US-A 4,853,230 such enteric coated preparations of different acid labile substances are described. Said preparations contain an alkaline core material comprising the active substance, a separating layer and an enteric coating layer.
- 55 [0010] Ordinary enteric coating layers, however, comprise compounds which contain acidic groups. If covered with such an enteric coating layer, the acid labile substance may rapidly decompose by direct or indirect contact with the acidic groups resulting in discoloration of the content and loss in content of the active compound with the passage of time. The discoloration can be avoided by applying some type of separating layer between the core material comprising the susceptible proton pump inhibitor and the enteric coating layer.
- [0011] Thus, there are a lot of patent applications describing such a separating layer between a core material com-

prising the pharmaceutically active substance and an enteric coating layer. See for instance, US-A 4,786,505, EP 0,277,741 and EP 0.342,522. The prior art techniques to apply at least two different layers on a pellet core or a tablet comprising an acid labile compound is rather complicated and there is a demand for finding new processes and formulations to simplify the manufacturing of such enteric coated articles comprising acid labile substances.

5

#### Summary of the invention.

10

[0012] According to one aspect of the invention a new pharmaceutical dosage form is provided in the form of an enteric coated tablet. Alternatively, individually enteric coated units are prepared and filled into a capsule, a sachet or included in a tableted multiple unit dosage form.

15

[0013] The present invention is characterized by the presence of a separating layer between an alkaline reacting core material comprising a pharmaceutically active acid labile substance and an enteric coating layer, wherein the separating layer comprises a water soluble salt of an enteric coating polymer.

20

[0014] According to a second aspect the present invention provides a process for the manufacture of two functionally different layers in one manufacturing step. By such a process a separating layer comprising a water soluble salt of an enteric coating polymer is obtained, as well as the enteric coating layer itself.

25

[0015] Thus, the present invention simplifies the preparation of enteric coated articles comprising a separating layer between a core material and an enteric coating layer by providing a new process for the manufacture of such dosage forms. According to said process the separating layer is formed by an in situ reaction between the enteric coating polymer and the alkaline core material comprising the pharmaceutically active substance.

#### Brief description of the Figures

30

[0016] Figure 1 is a photo showing a cross-section of a tablet manufactured according to the invention described in the present specification.

[0017] Figure 2 is a schematic drawing of the photo disclosed in Figure 1. The tablet has an enteric coating layer (3), which has been applied on an alkaline core material (1) comprising the pharmaceutically active substance. Between the enteric coating layer (3) and the core material (1) there is a separating layer (2) shown. The separating layer (2) is on the photo inked by a fluorescent colour.

35

#### Detailed description of the invention

40

[0018] One object of the present invention is to provide a new enteric coated pharmaceutical formulation comprising a core material that contains a proton pump inhibitor, one or more alkaline reacting compound(s) and optionally pharmaceutically acceptable excipients, which formulation has a water soluble separating layer and an enteric coating layer and wherein the core material is alkaline and the separating layer is being formed in situ during the enteric coating as a salt between the enteric coating polymer(s) and an alkaline reacting compound(s) in the core material.

45

[0019] Another object of the present invention is to provide a new process for the manufacture of such enteric coated pharmaceutical formulations comprising a core material of a proton pump inhibitor wherein a separating layer is formed in situ during the enteric coating by a reaction between the enteric coating polymer(s) and one or more alkaline reacting compound(s) in the core material, i.e. thereby a salt is formed between the enteric coating polymer(s) and the alkaline reacting compound(s).

50

[0020] The new pharmaceutical dosage form according to the invention is further characterized in the following way. Compacted tablets or individual cores (in the form of small tablets, small beads, granules or pellets) contain the proton pump inhibitor in the form of a racemate or one of its single enantiomers or an alkaline salt of said compound or one of its single enantiomers. The tablets or individual cores, that also comprise one or more alkaline reacting compound(s) which is in the position to form a water soluble salt by a reaction with an enteric coating material, are coated with one or more enteric coating layers.

55

[0021] The separating layer is formed in situ by a reaction between the enteric coating polymer(s) and the alkaline reacting compound(s) in the core material during the enteric coating process.

[0022] The core material for the manufacture of enteric coated pellets can be prepared according to two main principles. Firstly, seeds can be layered with the proton pump inhibitor, alkaline reacting compound(s) and necessary excipients to give an alkaline reacting core material, or the alkaline reacting core material can be prepared as substantially homogeneous cores or tablets comprising the proton pump inhibitor and the alkaline reacting compound(s).

60

[0023] The alkaline reacting compound(s) in the core material or tablet cores, necessary for an in situ reaction with the enteric coating polymer, is a substance in the position to form a water soluble salt with an enteric coating polymer. Such alkaline reacting compounds are for instance amino acids, such as lysine, arginine, ornithine, histidine, organic buffering compounds such as trometamine (i.e. Tris-buffer), N-amino sugars such as N-methyl-D-glucamine (i.e.

Meglumine ), N-ethyl-D-glucamine (i.e. Eglumine ), glucosamine, disodium -N-stearoyl-glutamate, heterocyclic amine derivatives such as piperazine or its hexahydrate, N-methylpiperazine, morpholine, 1-(2-hydroxyethyl)pyrrolidine, alkali salts of citric acid, tartaric acid, caproic acid or fatty acids, alkali metal phosphates, silicates or carbonates, sodium, potassium, magnesium, calcium or aluminium hydroxides and organic amines such as ethylamine, dicyclohexylamine or triethanolamine, or alkaline ammonium salts.

[0024] The core material as such should be an alkaline reacting core material, i.e. the amount of alkaline reacting compound(s) available in the core material should be enough to form a salt between the enteric coating polymer(s) and the alkaline reacting compound(s).

[0025] Thus, the concentration of alkaline reacting compound(s) in the core material (before applying the enteric coating polymer) is from approximately 0.1 mmol/g dry ingredients in the alkali containing part of the core material up to approximately 15 mmol/g, preferably the concentration shall be more than 0.3 mmol/g dry ingredients in the alkaline part of the core material.

[0026] The upper limit range is only restricted by the need to include a pharmaceutically active ingredient and excipients such as binders etc in the alkaline core material. The concentration of alkaline reacting compound(s) may be illustrated as follows. For a core material where, for instance, 10 % w/w of a proton pump inhibitor and 5 % w/w of excipients (binders, surfactants etc) are to be included, 85 % w/w remains to possible disposition to the alkaline reacting compound(s). For such a core material, this means that, if the alkaline reacting compound is sodium bicarbonate which has the rather low molecular weight of 84 u, the concentration of the alkaline material in the core material will be  $\{ (85/84)/100 \} \times 1\,000$ , i.e. approximately 9.9 mmol/g in the alkali containing part/layer.

[0027] One or more enteric coating layers are applied onto the prepared core material or tablets by using a suitable aqueous coating technique. The enteric coating material is dispersed and/or dissolved in an aqueous vehicle. As enteric coating polymer(s) one or more, separately or in combination, of the following can be used; methacrylic acid copolymers, cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate, polyvinyl acetate phthalate, cellulose acetate trimellitate, carboxymethylcellulose, shellac or other suitable enteric coating polymer(s).

[0028] The enteric coating layer(s) may contain pharmaceutically acceptable plasticizers to obtain desired mechanical properties, such as flexibility and hardness of the enteric coating layer(s).

The amount of plasticizer is optimized for each enteric coating formulation, in relation to selected enteric coating polymer(s), selected plasticizer(s) and the applied amount of said polymer(s). The mechanical properties of the enteric coating are especially important for a tableted multiple unit dosage form, i.e. the individually enteric coated units must withstand the compression into a tableted multiple unit dosage form without any significant effect on the acid resistance. Suitable plasticizers are for instance, but not restricted to, triacetin, citric acid esters, phthalic acid esters, dibutyl sebacate, cetyl alcohol, polyethylene glycols, polysorbates or other plasticizers.

[0029] The preparation of the core material containing the proton pump inhibitor and alkaline reacting compound(s) is described more in detail below. The individually enteric coated cores can be constituted according to different principles.

[0030] The active substance, the proton pump inhibitor, used as a racemate or one of its single enantiomers or an alkaline salt of said compound or one of its single enantiomers, mixed with the alkaline reacting compound(s) is applied on seeds and are used for further processing.

[0031] The seeds, which are to be layered with the active substances, can be water insoluble seeds comprising different oxides, celluloses, organic polymers and other materials, alone or in mixtures or water soluble seeds comprising different inorganic salts, sugars, non-pareils and other materials, alone or in mixtures. Further, the seeds may comprise active substance in the form of crystals, agglomerates, compacts etc. The size of the seeds is not essential for the present invention but may vary between approximately 0.1 and 2 mm. The seeds layered with active substance are produced either by powder or solution/suspension layering using for instance granulating or spray coating/layering equipment.

[0032] Before the seeds are layered, the active substance is mixed with alkaline reacting compound(s) and further components to obtain preferred handling and processing properties and suitable concentration of the active substance. Pharmaceutical constituents such as fillers, binders, lubricants, disintegrating agents, surfactants and other pharmaceutically acceptable additives, can be used. Binders are for example celluloses such as hydroxypropyl methylcellulose, hydroxypropyl cellulose and carboxymethylcellulose sodium, polyvinylpyrrolidone, sugars, starches and other pharmaceutically acceptable substances with cohesive properties. Suitable surfactants are found in the groups of pharmaceutically acceptable non-ionic or ionic surfactants such as for instance sodium lauryl sulfate or polysorbates.

[0033] Alternatively, the active substance mixed with alkaline compound(s) and further mixed with suitable constituents can be formulated into tablets or individual cores. Said tablets or cores may be produced by compression/extrusion/spherization or balling utilizing different processing equipments. The manufactured tablets or cores can further be layered with additional ingredients comprising active substance and alkaline reacting compound(s) and/or be used for further processing.

EP 1 174 136 A2

[0034] The active substance may optionally be mixed with alkaline pharmaceutically acceptable substance (or substances) for further stabilisation. Such substances can be chosen among, but are not restricted to, substances such as for instance the above mentioned alkaline reacting compounds or other alkaline reacting substances known by the skilled person in the art to be useful as stabilizers for acidic susceptible substances.

5 [0035] Alternatively, the aforementioned alkaline reacting core material can be prepared by the use of spray drying or spray congealing technique.

[0036] The prepared alkaline reacting core material in the form of tablets or pellets are spray coated with an aqueous enteric coating polymer dispersion/solution. The process parameters such as inlet air temperature, air flow, atomizer air flow and spraying rate are adjusted with respect to the equipment used for the process as well as the specific enteric 10 coating polymer(s). The inlet air temperature must not be such that the enteric coating polymer(s) will block in the spraying nozzles.

[0037] The invention is described more in detail by the following examples, which are not intended to limit the scope of the invention.

15 Example 1

[0038] Tablets containing lansoprazole and arginine are produced according to the following procedure. Firstly, dry ingredients are thoroughly mixed and then granulated with a solution in a laboratory mixer. The dried granules are mixed with lubricants etc. in a final mixing step.

20

Dry ingredients for granulation (for approx. 4000 tablets)	Concentration (mmol/g dry ingredients in the alkaline tablet core)
Lansoprazole L-arginine (passing 120 mesh) Microcrystalline cellulose	40.4 g 365.4 g 38.5 g

25

30

Granulating solution	
Distilled water	173 g

35

[0039] The solution is poured over the premixed powder mass during mixing. The wet granules are dried on a tray in a drying cabinet. The dried granules are milled to pass a 1.0 mm sieve. The granules are mixed with

40

Talc	3.1 g
Sodium dodecyl sulphate	20.8 g
Microcrystalline cellulose	19.2 g
Magnesium stearate	5.0 g

in a laboratory mixer, and then compressed into tablets having a size of 7 mm Ø and a weight of approximately 125 mg. The obtained tablets have a content of lansoprazole of 10 mg per tablet.

45 [0040] Obtained tablets are spray coated with the enteric coating dispersion defined below, in a Wurster equipped fluidized bed.

50

Enteric coating dispersion	
Water	80.0 g
Triethylcitrate	1.3 g
Na-laurylsulphate	0.2 g
Hydroxypropylmethylcellulose	
acetate succinate LF	6.3 g
Talc	1.9 g

55

[0041] This single coating step resulted in tablets having two polymeric layers with different characteristics. The inner layer is not soluble in acetone, as the outer layer, but soluble in water. Figure 1, obtained with confocal laser scanning

EP 1 174 136 A2

microscopy (CLSM) shows a cross-section of the tablet where the separating layer is easily detected as a layer having an intense fluorescence.

[0042] The separating layer is spontaneously formed *in situ* during the process, as a salt between the alkaline reacting compound and the enteric coating polymer.

5

Example 2

[0043] Core material containing the magnesium salt of (-)-omeprazole and the alkaline reacting compound trometamine (= tris-buffer) is prepared by extrusion and spheronization.

10

[0044] The powder mass is mixed in a laboratory mixer and then water is added.

Powder mixture		Concentration (mmol/g dry ingredients in the alkaline core material)
Magnesium salt of (-)-omeprazole	400 g	
Microcrystalline cellulose	300 g	
Trometamine	1000 g	4.1
PVP-XL	100 g	
Mannitol pwd	195 g	
Hydroxypropyl methylcellulose 6 cps	5 g	
Water	q.s.	

[0045] The powder mixture is mixed with the water and the wet mass is mixed to obtain a suitable consistency of the mass.

25

[0046] Extrusion is performed with an extruder fitted with 1.0 mm screen. The extrudate is formed into pellets on a spheronizer and dried in a fluidized bed drier.

[0047] 200 g of the obtained pellets are spray coated with the enteric coating dispersion described below, in a Wurster equipped fluidized bed.

30

Enteric coating dispersion		
Water	93.9 g	
Polyethylene glycol 400	4.6 g	
Eudragit™ L30D-55	151.5 g	

35

[0048] This single coating step resulted in pellets having two polymeric layers with different characteristics. The inner layer is not soluble in acetone as the outer layer, but soluble in water. The separating layer is spontaneously formed *in situ* during the process, as a salt between the alkaline reacting compound and the enteric coating polymer.

40

[0049] Enteric coated pellets having a separating layer are obtained. These pellets may be filled in capsules or sachets for oral administration.

Example 3

45

[0050] Core material containing omeprazole and N-methyl-D-glucamine (=meglumine) is prepared by extrusion and spheronization of the below described composition using the same procedure as in Example 2;

Powder mixture		Concentration (mmol/g dry ingredients in the alkaline core material)
Omeprazole	100.0 g	
Microcrystalline cellulose	50.0 g	
Meglumine	500.0 g	2.6
Mannitol pwd	297.0 g	
Sodium starch glycolate	48.0 g	
Sodium laurylsulphate	5.0 g	
Water	q.s.	

EP 1 174 136 A2

[0051] Obtained dried pellets/cores are spray coated with the enteric coating dispersion described below, in a Wurster equipped fluidized bed.

Enteric coating dispersion	
Water	93.9 g
Polyethylene glycol 400	4.6 g
Eudragit™ L30D-55	151.5 g

[0052] This single coating step resulted in tablets having two polymeric layers with different characteristics. The inner layer is not soluble in acetone, as the outer one, but soluble in water. The separating layer is spontaneously formed in situ during the process, as a salt between the alkaline reacting compound and the enteric coating polymer.

[0053] The obtained pellets having a separating layer and an enteric coating layer, are suitable for filling into hard gelatine capsules or sachets for oral administration.

Example 4

[0054] Core material containing magnesium salt of omeprazole and N-methyl-D-glucamine (meglumine) is prepared by layer coating in a Wurster equipped fluidized bed on sugar seeds. For this operation the following materials are used;

Substance	Amount	Concentration (mmol/g dry ingredients in the alkali containing layer)
Water purified	102 g	
Ethanol 99% (w/v)	102 g	
HPMC 6 cps	2 g	
N-methyl-D-glucamine	3.3 g	0.37
Magnesium salt of omeprazole	40 g	
Non Pareille	500 g	

[0055] First the water and ethanol were mixed whereafter the HPMC was dissolved in the obtained solution. N-methyl-D-glucamine and magnesium salt of omeprazole were dissolved/ suspended in the solution. The sugar cores (Non Pareille) were used as starting seeds for the formation of core material. A peristaltic pump was used to feed the spraying suspension, which was fed with a velocity of 3.9 g/min.

[0056] The Wurster apparatus was equipped with a 60 mm high insertion tube, having a diameter of 50 mm, positioned to leave a 10 mm slit below it. A spraying nozzle having a 0.8 mm opening was used. The atomizing air flow was 2.3 Nm<sup>3</sup>/h and air pressure used was 1.9 bar.

The inlet air temperature was 50° C and flow used 43 m<sup>3</sup>/h.

[0057] After the core formation step, 100 grams of the obtained core material was film-coated by spraying with an enteric coating dispersion as described below, using the same equipment as in the core formation step.

Enteric coating dispersion	
Water purified	183 g
Triethyl citrate	2.9 g
Sodium laurylsulphate	0.4 g
Hydroxypropyl methylcellulose acetate succinate LF	14.4 g
Talc	4.3 g

[0058] First the triethyl citrate was dissolved in the water, and thereafter the sodium laurylsulphate was added. The hydroxypropylmethylcellulose acetate succinate was dispersed in the solution, and then the talc was added. The dispersion was fed with a rate of 3.8 g/min.

[0059] Inlet air temperature used was 42 ° C and flow was set to 40 Nm<sup>3</sup>/h. Atomizing air flow used was 2.1 Nm<sup>3</sup>/h, obtained with a pressure of 1.7 bar.

[0060] After finalizing the spraying, the inlet air temperature is rised to 60° C and the product is kept at this temperature for appr. 5 minutes.

[0061] This single film-coating step resulted in cores having two polymeric coating layers with different characteristics.

EP 1 174 136 A2

The inner layer is not soluble in acetone, as the outer layer, but soluble in water. Using confocal laser scanning microscopy to study a cross-section of the cores from this example, the presence of an inner layer was confirmed.

[0062] The separating layer is spontaneously formed in situ during the process, as a salt between the alkaline reacting compound and the enteric coating polymer.

5

Example 5

10

[0063] A rotogravulator was used to produce spherical core units containing pantoprazole. As starting material inert sugar seeds (Non-Pareille) with an average size between 0.6 to 0.71 mm Ø was used. The sugar seeds were coating layered with the powder mixture described below, by spraying a 5 % solution of HPMC 6 cps in water.

15

[0064] The obtained core material containing pantoprazole was dried at 40°C for 16 hours in vacuum and then sieved to give granules between 0.6 mm to 1.25 mm Ø.

20

Starting material	
Non-Pareille	110 parts by weight

25

Powder mixture	Amount	Concentration (mmol/g dry ingredients in the alkali containing layer)
Pantoprazole	29.3 parts by weight	
L-Lysine	22.0 "	
Sucrose	36.7 "	
Corn starch	42.5 "	
Microcrystalline cellulose	36.7 "	0.88

30

Solution	
Hydroxypropyl methylcellulose	2.9 "
Water	(58.7 ")

35

[0065] 250 g of the core material produced in this way was spray coated with an enteric coating dispersion in a Wurster equipped fluidized bed apparatus. The dispersion was made by adding the mentioned ingredients in stated order, while stirring.

40

Dispersion		
Water	626.8 g	
Triethylcitrate	9.8 g	
Sodium-laurylsulphate	1.5 g	
Hydroxypropylmethylcellulose acetate succinate LF	49.2 g	
Talc	14.8 g	

45

[0066] Enteric coated pellets having a water soluble separating layer were obtained. These pellets may be filled in capsules or sachets for oral administration.

50

Example 6

55

Substance	Amount	Concentration (mmol/g dry ingredients in the alkaline tablet core)
Omeprazole	40.0 g	

## EP 1 174 136 A2

(continued)

Substance	Amount	Concentration (mmol/g dry ingredients in the alkaline tablet core)
Mannitol pwd	68.0 g	
Microcrystalline cellulose	35.0 g	
Polyvinylpyrrolidone cross-linked	30.0 g	
Hydroxypropylcellulose low-substituted	20.0 g	
L-arginine	5.3 g	0.14
Sodium laurylsulphate	2.0 g	
Water purified q.s.	approx 50 g	
Sodium stearylfumarate (SSF)	1.0 g	

[0068] The dry powders except for SSF were mixed to homogeneity. This mixture was moistened with the water and the wet mass dried on a tray in a drying oven. The obtained granules were milled to pass a screen with 0.8 mm apertures. Then the lubricant SSF was mixed with the granules using the same Kenwood mixer as before.

[0069] Cores having an average weight of 101 mg were compressed on a tabletting machine equipped with 6mm diameter punches.

[0070] After the core formation step, 50 grams of the obtained cores were film-coated by spraying an aqueous enteric coating dispersion as described below, using a Wurster equipped fluidized bed.

Enteric coating dispersion		
Substance	Amount	
Water purified	183 g	
Triethyl citrate	2.9 g	
Sodium laurylsulphate	0.4 g	
Hydroxypropylmethylcellulose acetate succinate LF	14.4 g	
Talc	4.3 g	

[0071] This single film-coating step resulted in cores having two polymeric coating layers with different characteristics.

The inner layer is not soluble in acetone, as the outer layer, but soluble in water.

[0072] The separating layer is spontaneously formed in situ during the process, as a salt between the alkaline reacting compound and the enteric coating polymer.

#### Example 7

[0073] Tablets, 7 mm in diameter containing omeprazole and disodiumhydrogenphosphate was prepared by mixing and granulating dry powder ingredients with a water solution containing sodium laurylsulphate, in a Kenwood mixer. For this operation the following materials are used:

Substance	Amount	Concentration (mmol/g dry ingredients in the alkaline tablet core)
Omeprazole	80 g	
Mannitol pwd	88 g	
Microcrystalline cellulose	132 g	
L-HPC	53 g	
Disodiumhydrogenphosphate dihydrate	104 g	1.12

EP 1 174 136 A2

Granulation liquid		
Water purified	80 g	
Sodium laurylsulphate	3 g	
Water purified q.s.		

Final mixing		
Sodium stearylfumarate (SSF)	10 g	
Polyvinylpyrrolidone crosslinked	50 g	

[0074] The dry powders except for SSF were mixed to homogeneity. This mixture was moistened first with the granulation liquid and then with water until satisfactory consistency of the mass. The wet mass was dried on a tray in a drying oven. The obtained granules were milled to pass a screen with 0.8 mm apertures and then the lubricant SSF and the disintegrating agent polyvinylpyrrolidone crosslinked were mixed with the obtained granules using the same Kenwood mixer as before.

[0075] Cores having an average weight of 130 mg were compressed on a tabletting machine equipped with 7 mm diameter punches.

[0076] After the core formation step, 50 grams of the obtained cores were film-coated by spraying with an aqueous enteric coating dispersion as described below, using a Wurster equipped fluidized bed.

Enteric coating dispersion		
Water purified	183 g	
Triethyl citrate	2.9 g	
Sodium laurylsulphate	0.4 g	
Hydroxypropyl methylcellulose acetate succinate LF	14.4 g	
Talc	4.3 g	

[0077] This single film-coating step resulted in cores having two polymeric coating layers with different characteristics. The inner layer is not soluble in acetone, as the outer layer, but soluble in water. The separating layer is spontaneously formed in situ during the process, as a salt between the inorganic alkaline reacting compound and the enteric coating polymer.

Reference Examples 1 and 2

[0078] Placebo tablets, 6 mm in diameter was prepared by mixing and granulating dry powder ingredients with water in a Kenwood mixer. For this operation the following materials are used;

Substance	Amount		Concentration (mmol/g dry ingredients in the alkali containing layer)	
	Ref.Ex. 1	Ref.Ex. 2	Ref.Ex. 1	Ref.Ex. 2
Mannitol pwd	161. 5 g	141.3 g		
Microcrystalline cellulose	38.5 g	38.5 g		
Na <sub>2</sub> HPO <sub>4</sub> ·2H <sub>2</sub> O	----	20.2 g		
Water purified q.s. approx	45 g	45 g	----	0.56
Sodium stearylfumarate (SSF)	1.0 g	1.0 g		

[0079] The dry powders except for SSF were mixed to homogeneity. This mixture was moistened with the water and the wet mass dried on a tray in a drying oven. The obtained granules were milled to pass a screen with 0.8 mm apertures. Then the lubricant SSF was mixed with the granules using the same Kenwood mixer as before.

[0080] Cores having an average weight of 93- 94 mg were compressed on a tabletting machine equipped with 6 mm diameter punches.

EP 1 174 136 A2

[0081] After the core formation step, 50 grams of each kind of the obtained cores were (separately) film-coated by spraying an aqueous enteric coating dispersion according to below, using a Wurster equipped fluidized bed.

Enteric coating dispersion	
Substance	Amount
Water purified	183 g
Triethyl citrate	2.9 g
Sodium laurylsulphate	0.4 g
Hydroxypropylmethylcellulose acetate succinate LF	14.4 g
Talc	4.3 g

[0082] These reference examples show that presence of the alkaline material in the core material composition is necessary for the formation of an in situ formed spontaneously developed separating layer.

[0083] For Reference Ex. 1, this single film-coating step resulted in cores having only one coating layer, being soluble in acetone. No separating layer was spontaneously formed.

[0084] For Reference Ex. 2, this single film-coating step resulted in cores having two polymeric coating layers with different characteristics. The inner layer is not soluble in acetone, as the outer layer, but soluble in water. The separating layer is spontaneously formed in situ during the process, as a salt between the alkaline reacting compound and the enteric coating polymer.

[0085] By using confocal laser scanning microscopy to study a cross-section of the cores from the Reference example 2, the presence of an inner layer was confirmed. In contrast, examining a cross-section of a core from Reference example 1, no inner layer was seen.

[0086] The best mode to practice the invention is by the formulations described in Examples 1 and 2.

[0087] The different active substances, i.e. proton pump inhibitors, are prepared according to information disclosed in the Patent specifications mentioned in page 6 of this specification.

[0088] The following pages of the description relate to preferred embodiments of the invention, wherein "embt./embts." means embodiment/embodiments.

1. An oral pharmaceutical dosage form comprising a core material that contains a proton pump inhibitor, one or more alkaline reacting compound(s) and optionally pharmaceutically acceptable excipients having a water soluble separating layer and an enteric coating layer characterized in that the core material is alkaline reacting and that the separating layer is being formed in situ during the enteric coating as a water soluble salt between the enteric coating layer polymer(s) and the alkaline reacting compound(s).

2. A dosage form according to embt. 1, wherein the alkaline reacting compounds are selected from the group of alkaline organic substances, hydroxides of alkali metals or one of their alkaline salts of phosphoric acid, carbonic acid or silicic acid, or an alkaline ammonium salt.

3. A dosage form according to embt. 2, wherein the alkaline reacting substance is a hydroxide of an alkali metal or an alkaline salt of phosphoric acid, carbonic acid or silicic acid, or an alkaline ammonium salt.

4. A dosage form according to embt. 2, wherein the alkaline reacting compound is an alkaline organic substance, e.g. an amino acid or a salt thereof, an alkaline amine or a derivative thereof, or an alkaline salt of a weak organic acid.

5. A dosage form according to embt. 2, wherein the alkaline organic substance is an amino acid, e.g. lysine, arginine, ornitine or histidine, or an alkaline amine or a derivative thereof, e.g. N-methyl-D-glucamine or trometamine.

6. A dosage form according to embt. 1, wherein the alkaline reacting compounds are present in a concentration of more than 0.1 mmol/g dry ingredients in the alkaline part of the core material.

7. A dosage form according to embt. 1, wherein the enteric coating polymer(s) is/are hydroxypropyl cellulose derivative(s), e.g. hydroxypropylmethylcellulose acetate succinate.

EP 1 174 136 A2


8. A dosage form according to embt. 1, wherein the enteric coating polymer is copolymerized methacrylic acid/methacrylic acid methyl esters.

9. A dosage form according to embt. 1, wherein the proton pump inhibitor is a compound of the general formula I or a pharmaceutically acceptable salt thereof or a pure enantiomer thereof in neutral form or in the form of an alkaline salt




15 wherein


$\text{Het}_1$  is




25 or




30  $\text{Het}_2$  is




or




or



40  $\text{X} =$



or



50

wherein

N in the benzimidazole moiety means that one of the carbon atoms substituted by R6-R9 optionally may be exchanged for a nitrogen atom without any substituents;

55

R1, R2 and R3 are the same or different and selected from hydrogen, alkyl, alkoxy optionally substituted by fluorine, alkylthio, alkoxyalkoxy, dialkylamino, piperidino, morpholino, halogen, phenyl and phenylalkoxy;

**EP 1 174 136 A2**

R<sub>4</sub> and R<sub>5</sub> are the same or different and selected from hydrogen, alkyl and aralkyl;

R'<sub>6</sub> is hydrogen, halogen, trifluoromethyl, alkyl and alkoxy;

5 R<sub>6</sub>-R<sub>9</sub> are the same or different and selected from hydrogen, alkyl, alkoxy, halogen, halo-alkoxy, alkylcarbonyl, alkoxycarbonyl, oxazolyl, trifluoroalkyl, or adjacent groups R<sub>6</sub>-R<sub>9</sub> form ring structures which may be further substituted;

10 R<sub>10</sub> is hydrogen or forms an alkylene chain together with R<sub>3</sub> and

R<sub>11</sub> and R<sub>12</sub> are the same or different and selected from hydrogen, halogen or alkyl; and alkyl groups, alkoxy groups and moieties thereof may be branched and straight C<sub>1</sub>-C<sub>9</sub> -chains or comprise cyclic alkyl groups, for example cycloalkylalkyl.

15 10. A dosage form according to embt. 1, wherein the proton pump inhibitor is omeprazole or an alkaline salt thereof.

11. A dosage form according to embt. 1, wherein the proton pump inhibitor is a pure enantiomer of omeprazole or an alkaline salt thereof.

20 12. A dosage form according to embt. 1, wherein the proton pump inhibitor is lansoprazole, one of its pure enantiomers or a pharmaceutically acceptable salt thereof.

13. A dosage form according to embt. 1, wherein the proton pump inhibitor is pantoprazole, one of its pure enantiomers or a pharmaceutically acceptable salt thereof.

25 14. A dosage form according to embt. 1, wherein the alkaline reacting core material is individual pellets intended for a capsule formulation or a tableted multiple unit dosage form.

15. A dosage form according to embt. 1, wherein the alkaline reacting core material is a tablet.

30 16. A dosage form according to embt. 1, wherein individually enteric coated pellets are compressed into a tableted multiple unit dosage form.

35 17. A process for the preparation of an oral, enteric coated pharmaceutical dosage form comprising a core material that contains a proton pump inhibitor, one or more alkaline reacting compounds and optionally pharmaceutically acceptable excipients having a water soluble separating layer and an enteric coating layer characterized in that an alkaline reacting core material is prepared and coated with an enteric coating polymer wherein a separating layer between the core material and the enteric coating layer is formed in situ by a reaction between the enteric coating polymer(s) and the alkaline reacting compound(s) in the core material during the application of the enteric coating onto the alkaline reacting core material.

40 18. An oral, pharmaceutical dosage form comprising a proton pump inhibitor as defined in any of embts. 1-16 for use in inhibiting gastric acid secretion in mammals and man.

45 19. Use of an oral pharmaceutical dosage form defined in any of embts. 1 - 16 for the manufacture of a medicament useful in the treatment of gastric acid related diseases.

**Claims**

- 50 1. An oral pharmaceutical dosage form comprising a core material that contains a proton pump inhibitor, one or more alkaline reacting compound(s) and optionally pharmaceutically acceptable excipients having a water soluble separating layer and an enteric coating layer characterized in that the core material is alkaline reacting and that the separating layer is being formed *in situ* during the enteric coating as a water soluble salt between the enteric coating layer polymer(s) and the alkaline reacting compound(s).
- 55 2. A dosage form according to claim 1, wherein the alkaline reacting compounds are selected from the group of an alkaline reacting organic substance, a hydroxide of alkali metal, an alkaline salt of phosphoric acid, carbonic acid

EP 1 174 136 A2

or silicic acid, or an alkaline ammonium salt.

3. A dosage form according to claim 2, wherein the alkaline reacting compound is a hydroxide of an alkali metal or an alkaline salt of phosphoric acid, carbonic acid or silicic acid, or an alkaline ammonium salt.
- 5 4. A dosage form according to claim 2, wherein the alkaline reacting compound is an alkaline organic substance, e.g. an amino acid or a salt thereof, an alkaline amine or a derivative thereof, or an alkaline salt of a weak organic acid.
- 10 5. A dosage form according to claim 2, wherein the alkaline organic substance is an amino acid, e.g. lysine, arginine, ornitine or histidine, or an alkaline amine or a derivative thereof, e.g. N-methyl-D-glucamine or trometamine.
6. A dosage form according to claim 1, wherein the alkaline reacting compounds are present in a concentration of more than 0.1 mmol/g dry ingredients in the alkaline part of the core material.
- 15 7. A dosage form according to claim 1, wherein the alkaline reacting compounds are present in a concentration of more than 0.3 mmol/g dry ingredients in the alkaline part of the core material.
8. A dosage form according to claim 1, wherein the enteric coating polymer(s) is/are hydroxypropyl cellulose derivative (s).
- 20 9. A dosage form according to claim 1, wherein the hydroxypropyl cellulose derivative is hydroxypropylmethylcellulose acetate succinate.
10. A dosage form according to claim 8, wherein the hydroxypropyl cellulose derivative is hydroxypropylmethylcellulose phtalate.
- 25 11. A dosage form according to claim 1, wherein the enteric coating polymer is methacrylic acid copolymer.
12. A dosage form according to claim 1, wherein the enteric coating polymer is copolymerized methacrylic acid/methacrylic acid methyl esters.
- 30 13. A dosage form according to claim 1, wherein the proton pump inhibitor is a compound of the general formula I or a pharmaceutically acceptable salt thereof or a pure enantiomer thereof in neutral form or in the form of an alkaline salt


35




wherein

45

$\text{Het}_1$  is




or




55


$\text{Het}_2$  is




or




or



X =



or



wherein

25 N in the benzimidazole moiety means that one of the carbon atoms substituted by R<sub>6</sub>-R<sub>9</sub> optionally may be exchanged for a nitrogen atom without any substituents;

30 R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub> are the same or different and selected from hydrogen, alkyl, alkoxy optionally substituted by fluorine, alkylthio, alkoxyalkoxy, dialkylamino, piperidino, morpholino, halogen, phenyl and phenylalkoxy;

35 R<sub>4</sub> and R<sub>5</sub> are the same or different and selected from hydrogen, alkyl and aralkyl;

R'<sub>6</sub> is hydrogen, halogen, trifluoromethyl, alkyl and alkoxy;

40 R<sub>6</sub>-R<sub>9</sub> are the same or different and selected from hydrogen, alkyl, alkoxy, halogen, halo-alkoxy, alkylcarbonyl, alkoxy carbonyl, oxazolyl, trifluoroalkyl, or adjacent groups R<sub>6</sub>-R<sub>9</sub> form ring structures which may be further substituted;

45 R<sub>10</sub> is hydrogen or forms an alkylene chain together with R<sub>3</sub> and

50 R<sub>11</sub> and R<sub>12</sub> are the same or different and selected from hydrogen, halogen or alkyl; and alkyl groups, alkoxy groups and moieties thereof may be branched and straight C<sub>1</sub>-C<sub>9</sub> - chains or comprise cyclic alkyl groups, for example cycloalkylalkyl.

14. A dosage form according to claim 1, wherein the proton pump inhibitor is omeprazole or an alkaline salt thereof.

45 15. A dosage form according to claim 1, wherein the proton pump inhibitor is a pure enantiomer of omeprazole or an alkaline salt thereof.

50 16. A dosage form according to claim 1 wherein the proton pump inhibitor is a magnesium salt of (-)-omeprazole.

55 17. A dosage form according to claim 1, wherein the proton pump inhibitor is lansoprazole, one of its pure enantiomers or a pharmaceutically acceptable salt thereof.

18. A dosage form according to claim 1, wherein the proton pump inhibitor is pantoprazole, one of its pure enantiomers or a pharmaceutically acceptable salt thereof.

55 19. A dosage form according to claim 1, wherein the alkaline reacting core material is formed to individual pellets intended for a capsule formulation or a tableted multiple unit dosage form.

**EP 1 174 136 A2**

20. A dosage form according to claim 1, wherein the alkaline reacting core material is formed to a tablet.
21. A dosage form according to claim 1, wherein individually enteric coated pellets are formed and compressed into a tableted multiple unit dosage form.
- 5 22. A process for the preparation of an oral, enteric coated pharmaceutical dosage form comprising a core material that contains a proton pump inhibitor, one or more alkaline reacting compounds and optionally pharmaceutically acceptable excipients having a water soluble separating layer and an enteric coating layer characterized in that an alkaline reacting core material is prepared and coated with an enteric coating polymer wherein a separating layer between the core material and the enteric coating layer is formed in situ by a reaction between the enteric coating polymer(s) and the alkaline reacting compound(s) in the core material during the application of the enteric coating onto the alkaline reacting core material.
- 10 23. Use of an enteric coated, oral pharmaceutical dosage form prepared according to any of claims 1 - 21 for the manufacture of a medicament useful in the treatment of gastric acid related diseases.
- 15

20

25

30

35

40


45

50

55


EP 1 174 136 A2


Fig. 1



EP 1 174 136 A2

Fig. 2





(19)

Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 1 174 136 A3

(12)

EUROPEAN PATENT APPLICATION

(88) Date of publication A3:  
23.04.2003 Bulletin 2003/17

(51) Int Cl.<sup>7</sup>: A61K 9/28, A61K 9/50,  
A61K 31/415, A61K 31/435,  
A61K 31/44

(43) Date of publication A2:  
23.01.2002 Bulletin 2002/04

(21) Application number: 01125523.9

(22) Date of filing: 09.02.1996

(84) Designated Contracting States:  
AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL  
PT SE

Designated Extension States:  
LT LV SI

(30) Priority: 09.02.1995 SE 9500478

(62) Document number(s) of the earlier application(s) in  
accordance with Art. 76 EPC:  
96902579.0 / 0 752 851

(71) Applicant: AstraZeneca AB  
151 85 Södertälje (SE)

(72) Inventors:  
• Lundberg, Per Johan  
431 83 Mölndal (SE)  
• Lövgren, Kurt  
431 83 Mölndal (SE)

(54) Oral pharmaceutical dosage form containing a proton pump inhibitor

(57) A new oral pharmaceutical dosage form comprising a core material that contains a proton pump inhibitor, one or more alkaline reacting compounds and optionally pharmaceutical excipients having a water soluble separating layer and an enteric coating layer. The core material as such is alkaline reacting and the separating layer between the alkaline reacting core material and the enteric coating layer is formed in situ as a water

soluble salt between the alkaline reacting compound(s) and the enteric coating polymer. The invention also describes a new efficient process for the manufacture of such a dosage form comprising two functionally different layers in one manufacturing step, and its use in medicine.



European Patent  
Office

## EUROPEAN SEARCH REPORT

Application Number  
EP 01 12 5523

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	US 4 786 505 A (ODA MINORU ET AL) 22 November 1988 (1988-11-22) * examples I-V *	1-23	A61K9/28 A61K9/50 A61K31/415 A61K31/435 A61K31/44
X	US 5 232 706 A (PALOMO COLL ALBERTO) 3 August 1993 (1993-08-03) * claims 1-11; example 1 *	1-23	
X	EP 0 519 365 A (BYK GULDEN LOMBERG CHEM FAB) 23 December 1992 (1992-12-23) * page 2, line 56 - page 3, line 3; claims 1-6; example 1 *	1-23	
X	US 4 853 230 A (LOVGREN KURT I ET AL) 1 August 1989 (1989-08-01) * claims 1-15 *	1-23	
-----			
TECHNICAL FIELDS SEARCHED (Int.Cl.7)			
A61K			
The present search report has been drawn up for all claims			
Place of search	Date of completion of the search	Examiner	
MUNICH	28 February 2003	ESTANOL, I	
CATEGORY OF CITED DOCUMENTS		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons ..... & : member of the same patent family, corresponding document	
<small>EPO FORM 1503.02 (P01/00)</small>			

**ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.**

EP 01 12 5523

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.  
 The members are as contained in the European Patent Office EDP file on  
 The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

28-02-2003

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4786505	A 22-11-1988	GB 2189698 A	04-11-1987
		SG 154294 G	17-03-1995
		AR 240250 A1	30-03-1990
		AT 84215 T	15-01-1993
		AT 140387 T	15-08-1996
		AT 184482 T	15-10-1999
		AU 601974 B2	27-09-1990
		AU 7191287 A	05-11-1987
		CA 1292693 A1	03-12-1991
		CN 87103284 A ,B	11-11-1987
		CY 1810 A	20-10-1995
		DD 273197 A5	08-11-1989
		DE 3751860 D1	22-08-1996
		DE 3751860 T2	21-11-1996
		DE 3783394 D1	18-02-1993
		DE 3783394 T2	06-05-1993
		DE 247983 T1	27-09-1990
		DK 215887 A	31-10-1987
		EP 0247983 A2	02-12-1987
		EP 0496437 A2	29-07-1992
		EP 0567201 A2	27-10-1993
		ES 2006457 T3	01-01-1994
		ES 2091971 T3	16-11-1996
		ES 2135443 T3	01-11-1999
		FI 871913 A ,B,	31-10-1987
		GR 89300058 T1	22-06-1989
		GR 3007434 T3	30-07-1993
		GR 3020734 T3	30-11-1996
		GR 3032101 T3	31-03-2000
		HK 52897 A	02-05-1997
		HK 135294 A	09-12-1994
		HR 920854 A1	31-10-1994
		HU 43954 A2	28-01-1988
		IE 61416 B1	02-11-1994
		JP 1863556 C	08-08-1994
		JP 62258320 A	10-11-1987
		JP 5069807 B	01-10-1993
		JP 2740993 B2	15-04-1998
		JP 5294831 A	09-11-1993
		KR 9104579 B1	06-07-1991
		LT 1683 A ,B	25-07-1995
		LV 10357 A	20-02-1995
		LV 10357 B	20-04-1996
		LV 5760 A4	20-12-1996
		NO 871790 A ,B,	02-11-1987
		NZ 220096 A	26-04-1990

ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.

EP 01 12 5523

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.  
 The members are as contained in the European Patent Office EOP file on  
 The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

28-02-2003

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
US 4786505	A	PH	25701 A	18-09-1991
		PL	265416 A1	21-07-1988
		PT	84785 A ,B	01-05-1987
		SI	8710681 A8	31-10-1996
US 5232706	A	ES	2024993 A6	01-03-1992
		ES	2032269 A6	16-01-1993
EP 0519365	A	AT	144416 T	15-11-1996
		AU	683411 B2	13-11-1997
		AU	1974692 A	12-01-1993
		BG	61796 B1	30-06-1998
		BG	98286 A	15-08-1994
		CA	2109697 A1	23-12-1992
		CN	1067809 A ,B	13-01-1993
		CZ	9302764 A3	13-07-1994
		DE	4219390 A1	24-12-1992
		DE	59207438 D1	28-11-1996
		DK	589981 T3	17-03-1997
		WO	9222284 A1	23-12-1992
		EP	0519365 A1	23-12-1992
		EP	0589981 A1	06-04-1994
		ES	2096080 T3	01-03-1997
		FI	935677 A	16-12-1993
		GR	3022154 T3	31-03-1997
		HK	1005851 A1	29-01-1999
		HR	920162 A1	31-08-1996
		IE	921733 A1	18-11-1992
		IL	102096 A	18-06-1996
		JP	3338052 B2	28-10-2002
		JP	6508118 T	14-09-1994
		KR	254021 B1	01-05-2000
		LV	11982 A	20-03-1998
		LV	11982 B	20-09-1998
		MX	9202961 A1	01-02-1993
		NO	934648 A	16-12-1993
		NZ	243147 A	21-12-1995
		PL	169951 B1	30-09-1996
		RO	117502 B1	30-04-2002
		RU	2089180 C1	10-09-1997
		SI	9200111 A	31-12-1992
		SK	128793 A3	08-06-1994
		US	5997903 A	07-12-1999
		ZA	9204386 A	24-02-1993
		ZW	9392 A1	17-02-1993

**ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.**

EP 01 12 5523

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.  
 The members are as contained in the European Patent Office EDP file on  
 The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

28-02-2003

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 4853230	A	01-08-1989	GB 2189699 A	04-11-1987
			AT 84211 T	15-01-1993
			AT 139692 T	15-07-1996
			AT 186639 T	15-12-1999
			AU 603568 B2	22-11-1990
			AU 7192287 A	05-11-1987
			CA 1302891 A1	09-06-1992
			CN 87103285 A ,B	18-11-1987
			CS 8703073 A2	13-06-1989
			CY 1860 A	16-04-1987
			DD 260222 B5	09-07-1998
			DE 3751851 D1	01-08-1996
			DE 3751851 T2	31-10-1996
			DE 3783386 D1	18-02-1993
			DE 3783386 T2	06-05-1993
			DE 244380 T1	08-02-1990
			DK 215987 A	31-10-1987
			EG 18517 A	30-04-1993
			EP 0244380 A2	04-11-1987
			EP 0502556 A1	09-09-1992
			EP 0565210 A2	13-10-1993
			ES 2010648 T3	16-07-1994
			ES 2089277 T3	01-10-1996
			ES 2137966 T3	01-01-2000
			FI 871914 A ,B,	31-10-1987
			GR 3032639 T3	30-06-2000
			GR 89300156 T1	12-03-1990
			GR 3007448 T3	30-07-1993
			GR 3020501 T3	31-10-1996
			HK 55497 A	09-05-1997
			HK 104095 A	07-07-1995
			HR 920855 A1	30-06-1995
			HU 44171 A2	29-02-1988
			IE 61837 B1	30-11-1994
			JP 1946242 C	10-07-1995
			JP 6067837 B	31-08-1994
			JP 62258316 A	10-11-1987
			KR 9504886 B1	15-05-1995
			LT 2260 R3	15-12-1993
			LV 5393 A3	10-03-1994
			LV 5753 A4	20-12-1996
			NO 871791 A ,B,	02-11-1987
			NZ 220097 A	26-04-1990
			PH 24440 A	25-06-1990
			PL 265417 A1	21-07-1988
			PT 84786 A ,B	01-05-1987

**ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.**

EP 01 12 5523

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.  
 The members are as contained in the European Patent Office EDP file on  
 The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

28-02-2003

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4853230 A		S1 8710680 A ,B	31-12-1996
		SU 1709894 A3	30-01-1992
		YU 68087 A1	31-08-1988
		ZA 8702379 A	30-12-1987

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER: \_\_\_\_\_**

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**